Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Stemina Biomarker Discovery Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action active for the company. This prosecution is localized in 1 distinct art unit, indicating a specific technical focus for the pending application. The company's matters are assigned to a distinct examiner, which centralizes the review process for this portfolio segment.
The busiest examiner, VOLKOV, ALEXANDER ALEXANDROVIC, is responsible for 1 pending office action, which accounts for all current pending activity in this technology area. Having 1 distinct examiner and 1 distinct art unit means that the company's progress in the Biotechnology & Pharmaceuticals sector is currently tied to a single examination path. This 1 pending office action represents the total administrative workload for Stemina Biomarker Discovery Inc. at this time. The concentration of prosecution under VOLKOV, ALEXANDER ALEXANDROVIC suggests a streamlined interaction with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VOLKOV, ALEXANDER ALEXANDROVIC | 1 | 29.5% | +21.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18884815 | IN VITRO ASSAY TO PREDICT CARDIOTOXICITY | VOLKOV, ALEXANDER ALEXANDROVIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18884815 | IN VITRO ASSAY TO PREDICT CARDIOTOXICITY | VOLKOV, ALEXANDER ALEXANDROVIC | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18884815 | IN VITRO ASSAY TO PREDICT CARDIOTOXICITY | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStemina Biomarker Discovery Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexander Alexandrovic Volkov has the most, with 1 of Stemina Biomarker Discovery Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
